Key Points
- Fractyl Health CEO Harith Rajagopalan bought 10,416 shares at $1.92 for $19,998.72, increasing his stake to 501,745 shares (a 2.12% rise) valued at about $963,350.40, per an SEC filing.
- Significant institutional buying occurred recently—Nantahala, Alyeska, Rosalind and Woodline made large Q3 purchases or increases—and analysts hold a consensus "Moderate Buy" with a $7.40 price target (four Buys, one Sell).
- The stock opened at $2.23 and was trading up ~9.3%, with a market cap of ~$305.6M, a negative P/E, and recent quarterly EPS of ($0.35) missing estimates while analysts expect -1.61 EPS for the year.
Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) CEO Harith Rajagopalan purchased 10,416 shares of Fractyl Health stock in a transaction that occurred on Thursday, December 4th. The stock was purchased at an average price of $1.92 per share, with a total value of $19,998.72. Following the transaction, the chief executive officer owned 501,745 shares in the company, valued at $963,350.40. This represents a 2.12% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Fractyl Health Trading Up 9.3%
NASDAQ GUTS opened at $2.23 on Tuesday. The firm's 50 day moving average price is $1.40 and its two-hundred day moving average price is $1.46. The company has a debt-to-equity ratio of 4.61, a quick ratio of 4.27 and a current ratio of 4.27. Fractyl Health, Inc. has a twelve month low of $0.82 and a twelve month high of $3.03. The stock has a market cap of $305.60 million, a price-to-earnings ratio of -0.97 and a beta of 1.93.
Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Equities analysts anticipate that Fractyl Health, Inc. will post -1.61 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in GUTS. Nantahala Capital Management LLC acquired a new stake in Fractyl Health in the 3rd quarter worth approximately $19,298,000. Alyeska Investment Group L.P. bought a new stake in shares of Fractyl Health during the 3rd quarter worth $8,981,000. Rosalind Advisors Inc. acquired a new position in Fractyl Health in the 3rd quarter valued at $7,950,000. Woodline Partners LP grew its stake in Fractyl Health by 821.1% in the 3rd quarter. Woodline Partners LP now owns 5,506,534 shares of the company's stock valued at $8,755,000 after buying an additional 4,908,693 shares during the last quarter. Finally, General Catalyst Group Management LLC bought a new position in Fractyl Health in the 2nd quarter worth $7,912,000.
Wall Street Analyst Weigh In
GUTS has been the topic of several research analyst reports. LADENBURG THALM/SH SH assumed coverage on Fractyl Health in a report on Thursday, August 28th. They issued a "buy" rating and a $3.60 target price on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of Fractyl Health in a research report on Wednesday, October 8th. Canaccord Genuity Group lifted their target price on shares of Fractyl Health from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Friday, November 21st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price target on shares of Fractyl Health in a research note on Tuesday, December 2nd. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Fractyl Health currently has an average rating of "Moderate Buy" and a consensus price target of $7.40.
Read Our Latest Analysis on GUTS
Fractyl Health Company Profile
(
Get Free Report)
Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
